Gefitinib, Trastuzumab, and Docetaxel in Treating Patients With Metastatic Breast Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

January 31, 2004

Primary Completion Date

August 31, 2015

Study Completion Date

August 31, 2015

Conditions
Breast Cancer
Interventions
BIOLOGICAL

trastuzumab

Cycle 1 loading dose of 8 mg/kg, followed by 6 mg/kg every 3 weeks for subsequent cycles.

DRUG

docetaxel

75 mg/m2 every three weeks, or 60 mg/m2 every three weeks depending on study findings

DRUG

gefitinib

250 mg daily or 250 mg daily on days 2 through 14 depending on study findings

Trial Locations (6)

90806

Breastlink Medical Group, Incorporated at Long Beach Memorial Medical Center, Long Beach

91105

City of Hope Medical Group, Pasadena

92543

Hematology Oncology Consultants-Hemet, Hemet

90211-1850

Tower Cancer Research Foundation, Beverly Hills

91010-3000

City of Hope Comprehensive Cancer Center, Duarte

90089-9181

USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER

NCT00086957 - Gefitinib, Trastuzumab, and Docetaxel in Treating Patients With Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter